In a patient who developed hyponatremia after initiating pregabalin and is currently taking pregabalin, duloxetine, perindopril, a thiazide diuretic, nebivolol, metformin, and furosemide, which medications should be discontinued to treat the hyponatremia?

Management of Hyponatremia in a Patient on Multiple Medications

Stop the thiazide diuretic immediately—it is the most likely culprit for hyponatremia in this patient, and continuing it poses significant risk for worsening electrolyte disturbances and neurological complications. 1, 2, 3

Primary Offending Medications to Discontinue

Thiazide Diuretic (First Priority)

• Thiazide diuretics are the number one cause of drug-induced hyponatremia, with the highest risk occurring in the first weeks after initiation but remaining elevated even after months of use 3, 4
• Stop the thiazide immediately in any patient presenting with hyponatremia, hypokalemia, or hypochloremia 5
• The European Society of Cardiology guidelines specifically recommend stopping thiazide diuretics in volume-depleted patients with hyponatremia 1
• Thiazides cause hyponatremia through multiple mechanisms: impaired urinary dilution, renal sodium and potassium loss, stimulation of ADH, and possible dipsogenic effects 4, 6
• Women and elderly patients are at particularly high risk for thiazide-associated hyponatremia 4, 7

Pregabalin (Second Priority)

• Pregabalin should be discontinued as it was the medication initiated just before hyponatremia developed 8, 9
• Pregabalin can cause SIADH (syndrome of inappropriate antidiuretic hormone secretion), though this is less commonly reported than with other medications 8
• A recent Spanish pharmacovigilance analysis identified pregabalin as a new safety signal for hyponatremia with statistically significant disproportionate reporting (ROR 2.5) 9
• The FDA label for pregabalin does not specifically list hyponatremia as a common adverse effect, but case reports demonstrate rapid improvement after discontinuation 10, 8

Duloxetine (Third Priority)

• Duloxetine should be stopped because SNRIs (serotonin-norepinephrine reuptake inhibitors) are well-established causes of SIADH 11, 12
• The combination of duloxetine with thiazide diuretics creates a synergistic risk for severe hyponatremia, particularly in elderly patients 12, 6
• SSRIs and SNRIs cause hyponatremia through inappropriate ADH release, with mechanisms distinct from but additive to thiazide effects 6
• The FDA label for duloxetine does not prominently feature hyponatremia warnings, but clinical evidence strongly supports this association 11, 12

Medications to Continue (with Monitoring)

Perindopril (ACE Inhibitor)

• Continue perindopril unless the patient develops symptomatic hypotension or significant renal impairment 1, 2
• ACE inhibitors do not directly cause hyponatremia and may actually help prevent thiazide-induced hypokalemia 5
• The 2023 sick day guidance recommends temporarily stopping ACE inhibitors only during acute volume depletion with vomiting/diarrhea, not for chronic hyponatremia management 2
• Monitor renal function closely; if creatinine rises >20-30% after stopping the thiazide, reassess within 7 days 13, 5

Nebivolol (Beta-Blocker)

• Continue nebivolol—beta-blockers are not associated with hyponatremia 1
• Beta-blockers do not interfere with sodium or water homeostasis 3

Metformin

• Continue metformin—it is not associated with hyponatremia 2
• The 2023 sick day guidance recommends stopping metformin only during acute illness with volume depletion, not for chronic hyponatremia 2

Furosemide (Loop Diuretic)

• Continue furosemide—loop diuretics actually decrease the risk of hyponatremia by promoting free water excretion 1, 3
• Loop diuretics are used therapeutically to treat hyponatremia in SIADH when combined with sodium supplementation 1, 14
• If the patient is volume overloaded, increasing the furosemide dose may help correct hyponatremia 1
• If the patient is volume depleted, the furosemide dose may need temporary reduction 1

Critical Drug Interaction Considerations

• The combination of thiazide + duloxetine creates multiplicative risk for severe hyponatremia through complementary mechanisms (impaired dilution + SIADH) 12, 6
• Elderly women taking both an SSRI/SNRI and a thiazide require especially careful monitoring, as this demographic has the highest risk for severe, symptomatic hyponatremia 6, 9
• The concurrent use of pregabalin (recently started) with pre-existing thiazide and duloxetine therapy likely triggered the acute presentation 8, 9

Immediate Management Steps

Discontinuation Protocol

1. Stop thiazide, pregabalin, and duloxetine immediately 1, 2, 8, 12
2. Check comprehensive metabolic panel within 24-48 hours after stopping these medications to assess sodium, potassium, chloride, and creatinine 5
3. Repeat electrolytes every 1-2 days until sodium normalizes 1, 5

Symptomatic vs. Asymptomatic Treatment

• If the patient has severe symptoms (confusion, seizures, reduced consciousness): administer 3% hypertonic saline as 100-150 mL IV bolus, targeting 6 mmol/L correction over 6 hours (but not exceeding 8 mmol/L total in 24 hours) 14, 15
• If the patient is asymptomatic or mildly symptomatic: initiate fluid restriction to 500-1000 mL/day and ensure adequate solute intake (salt and protein) 1, 15
• Avoid excessive hypotonic fluid consumption, which can worsen hyponatremia in SIADH 1

Electrolyte Repletion

• Replace potassium and chloride deficits if present, as these are common with thiazide use and impair the ability to correct hyponatremia 1
• Consider adding oral sodium chloride supplementation (e.g., 100 mEq three times daily) if sodium remains low despite fluid restriction 14

Monitoring for Overcorrection

• The most critical complication is overly rapid correction of chronic hyponatremia, which can cause osmotic demyelination syndrome 4, 15
• Target correction rate: no more than 8 mmol/L in the first 24 hours and 18 mmol/L over 48 hours 15
• If overcorrection occurs, administer hypotonic fluids or desmopressin to re-lower sodium 15
• Gradual correction with close clinical evaluation is preferable to rapid normalization toward laboratory reference ranges 15

Long-Term Considerations

Alternative Antihypertensive Strategy

• Do not restart the thiazide diuretic after hyponatremia resolves 5, 4
• If additional blood pressure control is needed after stopping the thiazide, consider adding a calcium channel blocker (e.g., amlodipine) rather than reintroducing a thiazide 5
• The combination of an ACE inhibitor (perindopril) plus a calcium channel blocker is a Grade A first-line regimen for hypertension without hyponatremia risk 5

Alternative Pain/Psychiatric Management

• For neuropathic pain, consider alternatives to pregabalin such as gabapentin (though it may carry similar risk) or topical agents 10
• For depression/anxiety, consider switching from duloxetine to a medication with lower SIADH risk after sodium normalizes, though all SSRIs/SNRIs carry some risk 3, 6
• Wait at least 2-4 weeks after sodium normalization before reintroducing any SIADH-associated medication, and monitor sodium closely 3

Reassessment Timeline

• Week 1: Check sodium, potassium, chloride, and creatinine 2-3 times to ensure appropriate correction rate 5
• Weeks 2-4: Continue weekly sodium checks until stable in normal range 5
• Long-term: If any SIADH-associated medication must be reintroduced, check sodium monthly for the first 3 months, then every 3-6 months 3, 9

Common Pitfalls to Avoid

• Do not restart the thiazide "at a lower dose"—even 12.5 mg chlorthalidone is associated with significant electrolyte depletion 5
• Do not combine fluid restriction with aggressive diuresis—this can worsen volume depletion and renal function 1, 14
• Do not assume hyponatremia will resolve without stopping the offending agents—continued exposure to thiazide + duloxetine will perpetuate the problem 12, 6
• Do not stop the ACE inhibitor or furosemide—these medications are not causing the hyponatremia and may actually be beneficial 1, 3